Researchers at Regeneron Pharmaceuticals Inc. Report New Data on Gene Therapy (Development of an Optimized Sec Method for Characterization of Genome Dna Leakage From Adeno-associated Virus Products).

Předmět:	BIOTECHNOLOGY industries PHARMACEUTICAL biotechnology industry ADENO-associated virus GENE therapy ANALYTICAL chemistry
Zdroj:	Gene Therapy Weekly; 11/25/2024, p2171-2171, 1p
Abstrakt:	Researchers at Regeneron Pharmaceuticals Inc. have developed an optimized method for characterizing genome DNA leakage from adeno-associated virus (AAV) products used in gene therapy. The study highlights the importance of understanding DNA leakage induced by freeze/thaw stress, which can impact product stability and efficacy. The optimized size-exclusion chromatography (SEC) method demonstrated satisfactory performance in quantifying DNA leakage across different AAV serotypes, offering valuable insights for AAV formulation and product development to ensure quality and stability. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu